Alicia C. Olivo - 21 Feb 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Signature
/s/ Alicia C. Olivo
Issuer symbol
NEO
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
4
Filing time
25 Feb 2025, 16:41:13 UTC
Previous filing
16 Jan 2025
Next filing
05 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEO Common Stock Options Exercise $0 +8,443 +21% $0.000000 47,857 23 Feb 2025 Direct F1
transaction NEO Common Stock Tax liability $0 -2,504 -5.2% $0.000000 45,353 23 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEO Stock Option (Right to Buy) Award $0 +107,450 $0.000000 107,450 21 Feb 2025 Common Stock 107,450 $13.05 Direct F3, F4
transaction NEO Restricted Stock Unit Award $0 +63,238 $0.000000 63,238 21 Feb 2025 Common Stock 63,238 $0.000000 Direct F5, F6
transaction NEO Restricted Stock Unit Options Exercise $0 -8,443 -33% $0.000000 16,886 23 Feb 2025 Common Stock 8,443 $0.000000 Direct F6, F7
holding NEO Stock Option (Right to Buy) 1,046 21 Feb 2025 Common Stock 1,046 $19.12 Direct F8
holding NEO Stock Option (Right to Buy) 1,024 21 Feb 2025 Common Stock 1,024 $27.34 Direct F9
holding NEO Stock Option (Right to Buy) 516 21 Feb 2025 Common Stock 516 $48.99 Direct F10
holding NEO Stock Option (Right to Buy) 1,117 21 Feb 2025 Common Stock 1,117 $46.10 Direct F11
holding NEO Stock Option (Right to Buy) 22,222 21 Feb 2025 Common Stock 22,222 $9.45 Direct F12
holding NEO Stock Option (Right to Buy) 55,332 21 Feb 2025 Common Stock 55,332 $10.05 Direct F13
holding NEO Stock Option (Right to Buy) 36,508 21 Feb 2025 Common Stock 36,508 $19.65 Direct F14
holding NEO Performance Stock Unit 19,508 21 Feb 2025 Common Stock 19,508 $0.000000 Direct F6, F15
holding NEO Restricted Stock Unit 13,006 21 Feb 2025 Common Stock 13,006 $0.000000 Direct F6, F16
holding NEO Stock Option (Right to Buy) 42,344 21 Feb 2025 Common Stock 42,344 $16.45 Direct F17
holding NEO Performance Stock Unit 25,330 21 Feb 2025 Common Stock 25,330 $0.000000 Direct F6, F18
holding NEO Restricted Stock Unit 59,382 21 Feb 2025 Common Stock 59,382 $0.000000 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
F2 Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
F3 This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F4 On February 21, 2025, Ms. Olivo was granted 107,450 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F5 On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F6 Once vested, the shares of common stock are not subject to expiration.
F7 On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F8 On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
F9 On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F10 On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F11 On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F12 On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F13 On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F14 On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F15 On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stockover the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
F16 On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F17 On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F18 On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant tothe performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.